RXSTNasdaqOphthalmic GoodsFiscal year ends December 31

RxSight, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$4.69+0.18 (+3.99%)

Close on Oct 19, 2026

Market cap: $194.59M
P/E (TTM): –
Dividend yield: –

Dividends

RxSight has not reported a dividend

No dividend per share appears in RxSight's annual filings since fiscal 2019.

Where these numbers come from

Parsed from the XBRL in RxSight's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is RXST.

Revenue growth-13.2% · median 9.3%

Gross margin77.5% · median 76.6%

Operating margin-43.2% · median -13.5%

Net margin-36.8% · median -6.9%

Company	Revenue	Growth
STAA	$339.59M	+51.3%
RXST	$127.58M	-13.2%
SGHT	$83.38M	+9.3%
LNSR	$60.26M	+3.3%
SI	$60.06M	+60.9%
IRIX	$51.57M	+3.7%

Company

Next earnings (est.): Nov 4, 2026, during market hours
Exchange: Nasdaq
Industry: Ophthalmic Goods
Fiscal year ends: December 31
Employees: 461
Held by institutions: 99.6%
Auditor: Ernst & Young LLP
SEC CIK: 1111485

Advertisement
300 × 250